keyword
MENU ▼
Read by QxMD icon Read
search

Pharmacoeconomics

keyword
https://www.readbyqxmd.com/read/28102877/feasibility-acceptability-and-construct-validity-of-eq-5d-in-systemic-sclerosis
#1
Roberta Gualtierotti, Francesca Ingegnoli, Luciana Scalone, Paolo Cortesi, Eleonora Bruschi, Maria Gerosa, Pier Luigi Meroni
BACKGROUND: Systemic sclerosis is a chronic disabling disease that is often associated with severe physical and psychological impairment. Nonetheless, health-related quality of life (HRQoL) in patients with systemic sclerosis is often left behind in clinical practice and research. One of the reasons for this lack of evaluation is the current use of tools, such as the short form-36 (SF-36) questionnaire, that are complete but complicated to use in everyday routine. Other self-reported outcome measures such as the health assessment questionnaire (HAQ) are simple, but specifically designed for physical disability...
January 19, 2017: Swiss Medical Weekly
https://www.readbyqxmd.com/read/28099369/the-cessation-of-anti-pd-1-antibodies-of-complete-responders-in-metastatic-melanoma
#2
Rahul Ladwa, Victoria Atkinson
The optimal duration of PD-1 antibodies for metastatic melanoma is unknown. In previous trials, there has been the potential to cease therapy if the patient achieves a complete response (CR). We aimed to assess the outcomes of patients who had ceased anti-PD-1 antibodies in this setting. A retrospective review was carried out of CR to PD-1-based therapy across two institutions. Patients were from the Pembrolizumab Named Patient Program (PEM NPP), Nivolumab monotherapy (NIVO), and reimbursed Pembrolizumab (r PEM)...
January 17, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28092219/the-21st-century-cures-act-pharmacoeconomic-boon-or-bane
#3
Roger Lee Mendoza
Barriers to entry in healthcare markets constitute one of the overriding concerns of health economists. The recent enactment of the 21st Century Cures Act in the United States is one landmark legislation that reduces statutory entry barriers to the discovery, development, testing and licensing of drugs and medical devices. However, it brings with it many critical challenges concerning the safety, efficacy and value of drugs and devices, along with novel opportunities for medical innovation and faster treatment of diseases...
January 16, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28076643/translation-and-cross-cultural-adaptation-of-the-rating-scale-for-countertransference-rsct-to-american-english
#4
Rafael Mondrzak, Camila Reinert, Andreia Sandri, Lucas Spanemberg, Eduardo L Nogueira, Mirella Bertoluci, Claudio Laks Eizirik, Nina Rosa Furtado
Introduction: The Rating Scale for Countertransference (RSCT) - originally, Escala para Avaliação de Contratransferência (EACT) - is a self-administered instrument comprising questions that assess 23 feelings (divided into three blocs, closeness, distance, and indifference) that access conscious countertransferential emotions and sentiments. This paper describes the process of translation and cross-cultural adaptation of the RSCT into American English. Methods: This study employed the guidelines proposed by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Task Force for Translation and Cultural Adaptation which define 10 steps for translation and cross-cultural adaptation of self-report instruments...
October 2016: Trends in Psychiatry and Psychotherapy
https://www.readbyqxmd.com/read/28068459/does-pharmacogenomic-testing-improve-clinical-outcomes-for-major-depressive-disorder-a-systematic-review-of-clinical-trials-and-cost-effectiveness-studies
#5
Joshua D Rosenblat, Yena Lee, Roger S McIntyre
OBJECTIVE: Pharmacogenomic testing has become scalable and available to the general public. Pharmacogenomics has shown promise for predicting antidepressant response and tolerability in the treatment of major depressive disorder (MDD). In theory, pharmacogenomics can improve clinical outcomes by guiding antidepressant selection and dosing. The current systematic review examines the extant literature to determine the impact of pharmacogenomic testing on clinical outcomes in MDD and assesses its cost-effectiveness...
January 3, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28064553/granulocyte-colony-stimulating-factors-in-the-prevention-of-febrile-neutropenia-review-of-cost-effectiveness-models
#6
Kelly Fust, Anju Parthan, Michael Maschio, Qing Gu, Xiaoyan Li, Gary H Lyman, Spiros Tzivelekis, Guillermo Villa, Milton C Weinstein
We reviewed the evolution of the methods used in cost-effectiveness analyses of granulocyte colony-stimulating factors (G-CSFs) in the primary and secondary prevention of febrile neutropenia (FN) in patients receiving myelosuppressive cancer chemotherapy. Areas covered: FN is a side effect of myelosuppressive chemotherapy associated with significant morbidity, mortality, and costs. The risk of FN may depend on the drugs used within a chemotherapy regimen, and an FN event may cause chemotherapy dose reductions or delays in subsequent cycles...
January 9, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28061992/recommend-upfront-consolidation-with-high-dose-melphalan-and-autologous-stem-cell-support
#7
REVIEW
Gunjan L Shah, Sergio A Giralt
The overall goal of treatment for multiple myeloma (MM) is to prolong survival for as long as possible with the minimal treatment burden for each patient. Consolidation with upfront high-dose melphalan and autologous hematopoietic stem cell transplantation (ASCT) can prolong progression-free and overall survival by deepening response. It thereby can improve quality of life by allowing patients to have a time on maintenance therapy along with infrequent office visits, making it cost-effective in many situations...
December 2016: Seminars in Oncology
https://www.readbyqxmd.com/read/28061899/selection-of-essential-medicines-for-south-africa-an-analysis-of-in-depth-interviews-with-national-essential-medicines-list-committee-members
#8
Velisha Ann Perumal-Pillay, Fatima Suleman
BACKGROUND: The South African (SA) public health system has employed an Essential Medicines List (EML) with Standard Treatment Guidelines (STGs) in the public sector since 1996. To date no studies have reported on the process of selection of essential medicines for SA EMLs and how this may have changed over time. This study reports on the decision making process for the selection of essential medicines for SA EMLs, over the years, as described by various members of the National Essential Medicines List Committee (NEMLC) and their task teams...
January 7, 2017: BMC Health Services Research
https://www.readbyqxmd.com/read/28051283/incremental-cost-effectiveness-pharmacoeconomic-assessment-of-hepatitis-c-virus-therapy-an-approach-for-less-wealthy-members-of-the-common-market
#9
Diana Mance, Davor Mance, Dinko Vitezić
AIM: To develop a new method of health-economic analysis based on a marginal approach. METHODS: We tested the research hypothesis that a detailed comparative a priori incremental cost-effectiveness analysis provides the necessary input for budget impact analysis about the proper order of introduction of new therapies, and thus maximizes the cost-effectiveness bounded by the total budget constraint. For the analysis we chose a combination therapy for the treatment of hepatitis C virus (HCV) genotype 1 (GT1) infection, which was approved by the European Medicine Agency in 2015...
December 31, 2016: Croatian Medical Journal
https://www.readbyqxmd.com/read/28049952/time-series-modeling-and-simulation-for-comparative-cost-effective-analysis-in-cancer-chemotherapy-an-application-to-platinum-based-regimens-for-advanced-non-small-cell-lung-cancer
#10
Yugo Chisaki, Nobuhiko Nakamura, Yoshitaka Yano
The purpose of this study was to propose a time-series modeling and simulation (M&S) strategy for probabilistic cost-effective analysis in cancer chemotherapy using a Monte-Carlo method based on data available from the literature. The simulation included the cost for chemotherapy, for pharmaceutical care for adverse events (AEs) and other medical costs. As an application example, we describe the analysis for the comparison of four regimens, cisplatin plus irinotecan, carboplatin plus paclitaxel, cisplatin plus gemcitabine (GP), and cisplatin plus vinorelbine, for advanced non-small cell lung cancer...
2017: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28025930/cost-effectiveness-of-treatment-sequences-of-chemotherapies-and-targeted-biologics-for-elderly-metastatic-colorectal-cancer-patients
#11
Rohan C Parikh, Xianglin L Du, Morgan O Robert, David R Lairson
BACKGROUND: Treatment patterns for metastatic colorectal cancer (mCRC) patients have changed considerably over the last decade with the introduction of new chemotherapies and targeted biologics. These treatments are often administered in various sequences with limited evidence regarding their cost-effectiveness. OBJECTIVE: To conduct a pharmacoeconomic evaluation of commonly administered treatment sequences among elderly mCRC patients. METHODS: A probabilistic discrete event simulation model assuming Weibull distribution was developed to evaluate the cost-effectiveness of the following common treatment sequences: (a) first-line oxaliplatin/irinotecan followed by second-line oxaliplatin/irinotecan + bevacizumab (OI-OIB); (b) first-line oxaliplatin/irinotecan + bevacizumab followed by second-line oxaliplatin/irinotecan + bevacizumab (OIB-OIB); (c) OI-OIB followed by a third-line targeted biologic (OI-OIB-TB); and (d) OIB-OIB followed by a third-line targeted biologic (OIB-OIB-TB)...
January 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28010146/national-reimbursement-listing-determinants-of-new-cancer-drugs-a-retrospective-analysis-of-58-cancer-treatment-appraisals-in-2007-2016-in-south-korea
#12
Eun-Sook Kim, Jung-Ae Kim, Eui-Kyung Lee
BACKGROUND: Since the positive-list system was introduced, concerns have been raised over restricting access to new cancer drugs in Korea. Policy changes in the decision-making process, such as risk-sharing agreement and the waiver of pharmacoeconomic data submission, were implemented to improve access to oncology medicines, and other factors are also involved in the reimbursement for cancer drugs. The aim of this study is to investigate the reimbursement listing determinants of new cancer drugs in Korea...
January 3, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28008301/iloperidone-in-the-treatment-of-schizophrenia-an-evidence-based-review-of-its-place-in-therapy
#13
REVIEW
Fernanda S Tonin, Astrid Wiens, Fernando Fernandez-Llimos, Roberto Pontarolo
INTRODUCTION: Schizophrenia is a chronic and debilitating mental disorder that affects the patient's and their family's quality of life, as well as financial costs and health care settings. Despite the variety of available antipsychotics, optimal treatment outcomes are not always achieved. Novel drugs, such as iloperidone, can provide more effective, tolerable and safer strategies. AIM: To review the evidence for the clinical impact of iloperidone on the treatment of patients with schizophrenia...
2016: Core Evidence
https://www.readbyqxmd.com/read/28005036/-evaluation-of-the-pharmacoeconomic-efficacy-of-prestance-in-the-treatment-of-hypertensive-patients-on-the-basis-of-the-results-of-the-potential-program
#14
I N D'yakov, M G Glezer
AIM: To pharmacoeconomically estimate the use of a fixed-dose combination of perindopril and amlodipine in the treatment of hypertensive patients. MATERIAL AND METHODS: A pharmacoeconomic study was conducted on the basis of the Russian postmarketing observational open program POTENTIAL, which included the estimation of direct and indirect costs associated with the addition of a fixed-dose combination of perindopril and amlodipine to conventional therapy for hypertension in patients who had not achieved adequate blood pressure (BP) control...
2016: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/27996984/-consensus-document-a-model-of-integrated-management-of-patients-with-psycomotor-agitation
#15
(no author information available yet)
Psychomotor agitation (PMA) is a heterogeneous clinical syndrome associated with a widenumber of pathological conditions. The currently available recommendations and guidelines on PMA correct assessment and management are significantly dishomogeneous and suffer from a lack of standardization, especially regarding pharmacological interventions. Based on this deficiency, and on multidisciplinary nature of PMA, that includes factors shared by different health professionals other than pharmacoeconomic and risk management aspects, we started a project aimed to elaborate a shared model of integrated management for PMA patients...
November 2016: Rivista di Psichiatria
https://www.readbyqxmd.com/read/27987631/economic-evaluations-of-multicomponent-disease-management-programs-with-markov-models-a-systematic-review
#16
REVIEW
Florian Kirsch
BACKGROUND: Disease management programs (DMPs) for chronic diseases are being increasingly implemented worldwide. OBJECTIVES: To present a systematic overview of the economic effects of DMPs with Markov models. The quality of the models is assessed, the method by which the DMP intervention is incorporated into the model is examined, and the differences in the structure and data used in the models are considered. METHODS: A literature search was conducted; the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement was followed to ensure systematic selection of the articles...
December 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27987629/translating-pharmacometrics-to-a-pharmacoeconomic-model-of-copd
#17
Julia F Slejko, Richard J Willke, Jakob Ribbing, Peter Milligan
BACKGROUND: A model-based meta-analysis (MBMA) is a type of meta-regression that uses nonlinear mixed-effects models estimated on trial-level data to relate patient and trial characteristics, dosing, biomarkers, and outcomes of treatment. OBJECTIVES: To use a pharmacometric MBMA within a pharmacoeconomic model of chronic obstructive pulmonary disease (COPD). METHODS: A Markov microsimulation model was developed to estimate monthly changes in the key disease severity metrics of COPD (forced expiratory volume in 1 second [FEV1] and exacerbations) to compare a hypothetical drug that increases FEV1 to usual care...
December 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27986202/pharmacoeconomics-outcomes-research-health-technology-assessment-comparative-effectiveness-patient-centered-outcomes-research-in-latin-america-2016-brief-update
#18
EDITORIAL
Federico Augustovski, Jaime Caro, Marcos Bosi Ferraz, Victor Zárate
No abstract text is available yet for this article.
December 2016: Value in Health Regional Issues
https://www.readbyqxmd.com/read/27973280/a-parallel-observational-and-prospective-study-on-pharmacoeconomic-analysis-and-prescribing-pattern-of-antibiotics-in-infectious-diseases
#19
C Chenna, S Bandari, M Pal, D Gaddam
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27973239/drug-utilizaton-and-pharmacoeconomic-analysis-of-geriatric-patients-in-a-tertiary-care-teaching-hospital
#20
T S Mohamed Saleem, C Gopinath, K Mahesh, T Sharmila Bhanu
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
14697
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"